BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Shanghai
BEGIN:STANDARD
TZOFFSETFROM:+0800
TZOFFSETTO:+0800
TZNAME:CST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250731T120000
DTEND;TZID=America/Los_Angeles:20250731T130000
DTSTAMP:20260715T122619
CREATED:20250512T144339Z
LAST-MODIFIED:20250513T235311Z
UID:41960-1753963200-1753966800@solvecfs.org
SUMMARY:Probing Functional Autoantibodies in Patients with ME/CFS
DESCRIPTION:Dr. Akiko Iwasaki (Sterling Professor of Immunobiology and Molecular\, Cellular and Developmental Biology at Yale University) is the first recipient of Solve’s ME/CFS Catalyst Award in support of her study\, “Probing Functional Autoantibodies in Patients with ME/CFS.” \nIn this webinar\, Dr. Iwasaki will talk to Solve CEO Emily Taylor about the study\, which focuses on a crucial and emerging area of investigation: the role of autoantibodies—antibodies that mistakenly target a person’s own tissues—in the long-term neurological symptoms seen in patients with ME/CFS. \nDr. Iwasaki’s lab will investigate whether these autoantibodies can actually cause symptoms such as fatigue\, pain\, cognitive issues\, and motor dysfunction by introducing patient-derived antibodies into mice and analyzing their effects. The team will also use an advanced technology (called HuProt) to scan all human proteins to find which ones are targeted by specific autoantibodies. Autoantibodies against specific human proteins may be effective biomarkers—measurable features that help us diagnose patients quicker or customize how we treat each patient. \nThe study is remarkable because it: \n• Links Autoimmunity to ME/CFS: Helps determine whether immune system dysfunction is a root cause of neurological [SB3] symptoms in ME/CFS. \n• Lays the Groundwork for Targeted Treatments: Could identify which patients benefit most from existing immune-based therapies (like B-cell depletion or antibody-blocking drugs). \n• Advances Diagnostic Tools: Could find biomarkers that lead to the development of long-overdue diagnostic tests. \n• Bridges the Gap Between Long COVID and ME/CFS: Builds on recent research in long COVID\, creating momentum for both communities. \n• Centers Patient Experience: Is directly informed by the real-life neurological symptoms and struggles of people living with ME/CFS. \n  \nAfter her presentation and as time allows\, Dr. Iwasaki will take questions from the audience. \nRegister here: \nhttps://us02web.zoom.us/webinar/register/WN_byWyT5GoQfyLwYP3t0qruw
URL:https://solvecfs.org/event/probing-functional-autoantibodies-in-patients-with-me-cfs/
CATEGORIES:Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/05/IwasakiSolveWebinarV412pmPT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20241218T100000
DTEND;TZID=America/Los_Angeles:20241218T110000
DTSTAMP:20260715T122619
CREATED:20241111T193438Z
LAST-MODIFIED:20241203T172519Z
UID:41153-1734516000-1734519600@solvecfs.org
SUMMARY:The Future of IACCI and Long Covid Research: ME/CFS and the Unfinished work of the COPVS Task Force
DESCRIPTION:**NEW TIME AND DATE!** \nIn 2021 the National Institutes of Health (NIH) launched the RECOVER Initiative\, a patient-centered\, integrated\, adaptive research network created to study Long Covid. Included in the RECOVER Initiative infrastructure was the Commonalities with Other Post-Viral Syndromes Task Force. \nThe Task Force included Solve President and CEO Emily Taylor\, Dr. Leonard Jason (Professor of Psychology at DePaul University and the Director of the Center for Community Research)\, and other well-known ME/CFS experts and played a crucial role in fostering collaboration among researchers\, clinicians\, and patient advocates. It also facilitated the exchange of knowledge and identified common data elements\, treatment strategies\, and diagnostic criteria. This multidisciplinary approach was essential for advancing our understanding of post-viral illnesses and developing effective interventions. \nThe Task Force concluded that Long Covid researchers can learn from ME/CFS efforts to identify key symptoms\, provide explicit criteria for when a symptom meets the threshold for being considered a problem\, and employ tactics to ensure that consistent information is elicited from patient interviews across settings. \nThe Task Force published a paper on their findings in December 2023 and was then disbanded by NIH. However\, there is clearly still a need to educate care providers\, researchers\, and the public about the connection between ME/CFS and Long Covid. \nIn this webinar\, Emily Taylor and Dr. Jason will discuss their findings and what they signal for the future of research on ME/CFS\, Long Covid\, and other infection-associated chronic conditions and illnesses (IACCIs). The session will conclude with the launch of an important advocacy action.
URL:https://solvecfs.org/event/the-future-of-iacci-and-long-covid-research-me-cfs-and-the-unfinished-work-of-the-copvs-task-force/
CATEGORIES:Advocacy,Long Covid,Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/11/500LennyJasonCOPVSIG121824.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20241011T090000
DTEND;TZID=America/Los_Angeles:20241011T100000
DTSTAMP:20260715T122619
CREATED:20240918T204343Z
LAST-MODIFIED:20240918T204343Z
UID:40996-1728637200-1728640800@solvecfs.org
SUMMARY:ICUE Webinar: Uniting Voices\, Amplifying Impact: National Organizations Collaborating to Support Our IACC Communities
DESCRIPTION:Please join us for the final\, culminating webinar of the Infection-Associated Chronic Conditions Understanding and Engagement (ICUE) project\, where we will discuss the findings and results from the project as well as on-going efforts to collaborate across the IACC community on advancing awareness\, clinical care\, patient support and research. \nDuring this webinar\, you will hear from ICUE project leadership from the COVID-19 Longhauler Advocacy Project\, Patient-Led Research Collaborative\, and Solve M.E.\, as well as leading experts in IACC education\, clinical care\, and research. At the conclusion of the presentations\, we will take questions and answers. \nThis webinar is an opportunity to learn and identify ways to engage and collaborate. Patients\, clinicians\, researchers\, and various other stakeholders all have vital roles to play\, both independently and collaboratively\, in advancing the understanding and management of IACCs. By working together\, we can raise awareness to advance patient-centered research\, enhance clinical care\, and improve educational outreach\, ultimately leading to better health outcomes for all affected individuals.  \nWe look forward to your participation in this important discussion. Please confirm your attendance by October 10th and join us in our efforts to advance the understanding and management of IACCs. Your involvement is crucial\, and we hope to see you there. \nUNITING VOICES\, AMPLIFYING IMPACT: COLLABORATING TO SUPPORT OUR IACC COMMUNITIES\nFriday\, October 11\, 2024\n9 am PT /12 pm ET \nRegistration link:\nhttps://us06web.zoom.us/webinar/register/WN_JOGSRf0ZQsu0ueVkp2HuWw#/registration \n 
URL:https://solvecfs.org/event/icue-webinar-uniting-voices-amplifying-impact-national-organizations-collaborating-to-support-our-iacc-communities/
CATEGORIES:Advocacy,Long Covid,Research,Solve M.E. Leadership
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/09/icue-graphic.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240910T120000
DTEND;TZID=America/Los_Angeles:20240910T130000
DTSTAMP:20260715T122619
CREATED:20240724T232700Z
LAST-MODIFIED:20240724T232804Z
UID:40840-1725969600-1725973200@solvecfs.org
SUMMARY:Solve Author Series:  Dr. Peter Rowe Discusses "Living Well with Orthostatic Intolerance: A Guide to Diagnosis and Treatment"
DESCRIPTION:Orthostatic intolerance (OI) describes a group of circulatory disorders whose symptoms are characterized by a dramatic drop in blood flow to the brain when people are sitting for long periods or standing still. It is often associated with other acute issues\, such as substantial drops in blood pressure\, tachycardia\, dizziness\, fainting\, or other long-term problems\, including ME/CFS and Long Covid.  \nIn his new book\, Living Well with Orthostatic Intolerance: A Guide to Diagnosis and Treatment\, Peter Rowe\, MD\, (Director of the Chronic Fatigue Clinic at Johns Hopkins Children’s Center and member of Solve M.E.’s Research Advisory Council) provides an overview of OI and its causes\, diagnosis\, symptom management and more.  \nIn this installment of our author spotlight series\, Solve President and CEO Emily Taylor talks to Dr. Rowe about his indispensable new guide for those diagnosed with the disorder\, their families\, and physicians. \nGuided by decades of research on managing and treating OI patients\, Dr. Rowe will provide illustrative case studies to help explain the disease and answer questions from attendees. \nPurchase a copy of Living Well with Orthostatic Intolerance: A Guide to Diagnosis and Treatment via Johns Hopkins University Press or Amazon. \nTuesday\, September 10\, 2024\n12-1 pm PT / 3-4 pm ET\nRegister here:\nhttps://us02web.zoom.us/webinar/register/WN_8pUWIfiqSvaL_d8gByvbUg
URL:https://solvecfs.org/event/solve-author-series-dr-peter-rowe-discusses-living-well-with-orthostatic-intolerance-a-guide-to-diagnosis-and-treatment/
CATEGORIES:Long Covid,Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/07/Rowe-Webinar-Sept.-2024-IG-500.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240510T090000
DTEND;TZID=America/Los_Angeles:20240510T120000
DTSTAMP:20260715T122619
CREATED:20240429T164557Z
LAST-MODIFIED:20240429T164702Z
UID:40388-1715331600-1715342400@solvecfs.org
SUMMARY:World ME Day: Bridging Borders – Global Voices from the World ME Alliance
DESCRIPTION:Solve is a proud co-founder of the World ME Alliance and we invite you to join us this year for the World ME Day event Bridging Borders – Global Voices from the World ME Alliance! \nSolve M.E. President and CEO and World ME Alliance Co-Chair Emily Taylor will represent Solve as one of the many nonprofit organizations from across the globe showcasing our work to build a #GlobalVoiceForME. \nTune in on May 10th at 9am PT\, 12pm ET\, 5pm BST\, 6pm CEST. \nRSVP on Facebook here: https://www.facebook.com/events/974991507395331/ \nThis event will be livestreamed\, allowing individuals from around the world to tune in\, in real-time. The event will be available to watch afterward on Facebook. \nOr you can register here to join us for the event on Zoom (limited spaces): https://worldmealliance.org/2024/04/register-for-our-live-event-bridging-borders-global-voices-from-the-world-me-alliance/ \nEmily will be joined by speakers from around the world\, including South Africa\, Czechia\, Italy\, France\, and more! \nWith the World ME Alliance\, Solve is bridging borders\, forging connections\, and building toward a better future for people with ME. \n 
URL:https://solvecfs.org/event/world-me-day-bridging-borders-global-voices-from-the-world-me-alliance/
CATEGORIES:Advocacy,Conference,Research,Solve M.E. Leadership
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/04/WorldMEAllianceEvent_5.10.24.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240126T120000
DTEND;TZID=UTC:20240126T130000
DTSTAMP:20260715T122619
CREATED:20240123T224519Z
LAST-MODIFIED:20240125T213444Z
UID:39759-1706270400-1706274000@solvecfs.org
SUMMARY:January 2024 Advocacy Cafe Chat
DESCRIPTION:Join us for this month’s Advocacy Cafe Chat! In this session\, Solve’s Vice President of Advocacy and Engagement Emily Taylor will review our recently updated Policy Advocacy Statement\, which drives our decisions about the advocacy and engagement work we do here at Solve. Tune in to share your views about the updated Solve Policy Advocacy Statement! \nPlease note — no registration is required. Join at this link.
URL:https://solvecfs.org/event/january-2024-advocacy-cafe-chat/
CATEGORIES:Advocacy,Advocacy Week 2024,Solve M.E. Leadership
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/01/Advocacy-Cafe-Jan-2024_500.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230417
DTEND;VALUE=DATE:20230423
DTSTAMP:20260715T122619
CREATED:20230207T011136Z
LAST-MODIFIED:20230207T162649Z
UID:37652-1681689600-1682207999@solvecfs.org
SUMMARY:Advocacy Week 2023
DESCRIPTION:Advocacy Week 2023 will take place virtually and in person throughout the week of April 17th to April 22nd\, 2023!  \nAdvocacy Week is a nationwide advocacy effort to connect people with ME/CFS\, Long COVID\, and associated conditions; scientists; clinicians\, and caregivers to share their unique stories with Congress. Our ultimate goal is to make ME/CFS\, Long COVID\, and associated conditions widely understood\, diagnosable\, and treatable. \nThere are actions for every energy level and ability to join\, from social media posts to virtual meetings with Congressional leaders. This year we will be offering both virtual and in-person (Washington DC) events.  \n\n\n\n\nAdvocacy Week 2023  \nMonday\, April 17th\, 2023 – Training Day – Washington DC & Virtual \nTuesday\, April 18th\, 2023 – Senate Advocacy Day – Washington DC \nWednesday\, April 19th\, 2023 – Social Media Action Day – Virtual \nThursday\, April 20th\, 2023 – House Advocacy Day – Virtual \nFriday\, April 21st\, 2023 – EmPOWER ME Day – Virtual \nFor registration and more event details\, visit StopTheLongHaul.org.
URL:https://solvecfs.org/event/advocacy-week-2023/
CATEGORIES:Advocacy,Advocacy Week 2023,Solve M.E. Leadership
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/02/Advo-Week-2023-Announcement-Graphic.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Shanghai:20230221T100000
DTEND;TZID=Asia/Shanghai:20230221T130000
DTSTAMP:20260715T122619
CREATED:20230131T184624Z
LAST-MODIFIED:20230216T234324Z
UID:37499-1676973600-1676984400@solvecfs.org
SUMMARY:Solve M.E. and BIO co-host "Long Covid: What Will It Take To Accelerate Therapeutic Progress?"
DESCRIPTION:Solve M.E. and The Biotechnology Innovation Organization (BIO) will co-host a three-hour virtual event “Long Covid: What Will It Take to Accelerate Therapeutic Progress?” on Tuesday\, February 21 from 10:00 AM – 1:00 PM PT (1:00 – 4:00 PM ET).  \nOur goal is to convene stakeholders to advance research and development to diagnose and treat Long Covid\, ME/CFS\, and other post-infection diseases. By increasing awareness among drug developers to the unmet needs of our communities\, we hope to inspire these industry players to study these diseases and create therapeutic breakthroughs.  \nThe session will establish a knowledge base of emerging research in Long Covid and existing body of data in other post-infection diseases (such as myalgic encephalomyelitis/chronic fatigue syndrome\, dysautonomia\, mast cell activation\, and others). The session also will feature solution-oriented perspectives from government\, academic\, and industry researchers\, patient groups\, funding sources\, and policymakers.  \nHosts: \n\nOved Amitay\, R.Ph.\, M.Sc.\, President and CEO of Solve M.E. Christopher Austin\, MD\, CEO-Partner\, Flagship Pioneering\nCartier Esham\, PhD\, Chief Science Officer\, Biotechnology Innovation Organization (BIO)\n\nOpening Remarks: \n\nUS Senator\, Tim Kaine\nRachel L. Levine\, M.D.\, Admiral\, U.S. Public Health Service\, U.S. Department of Health and Human Services\n\nSpeakers: \n\nAkiko Iwasaki\, PhD\, Sterling Professor of Immunobiology (Microbial Diseases)\, Yale School of Medicine\nBruce Patterson\, MD\, CEO & Founder\, IncellDx\nChristopher Austin\, MD\, CEO-Partner\, Flagship Pioneering\nDavid Putrino\, PhD\, Associate Professor\, Rehabilitation and Human\nJulie Gerberding\, MD\, MPH\, CEO\, Foundation for the National Institutes of Health\nKatie Bach\, MBA\, Nonresident Senior Fellow\,Brookings Institution\nLisa McCorkell\, MPP\, Co-Founder\, Patient-Led Research Collaborative\nMargaret Koziel\, MD\, SVP\, Chief Medical Officer\, Axcella Therapeutics\nPriti Patel\, MD\, MPH\, Senior Advisor for Post-COVID Conditions\, Centers for Disease Control and Prevention\nRachel L. Levine\, M.D.\, Admiral\, U.S. Public Health Service\, U.S. Department of Health and Human Services\nSeth Lederman\, MD\, Co-Founder\, CEO & Chairman\, Tonix Pharmaceuticals\nThomas Equels\, M.S.\, J.D.\, CEO\, AIM Immunotech\nWalter Koroshetz\, MD\, Director\, National Institute of Neurological Disorders and Stroke (NINDS)\n\nSolve M.E. is a non-profit organization that serves as a catalyst for critical research into diagnostics\, treatments\, and cures for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)\, Long Covid and other post-infection diseases.  \nBIO is the world’s largest advocacy association representing member companies\, state biotechnology groups\, academic and research institutions\, and related organizations across the United States and in 30+ countries.
URL:https://solvecfs.org/event/solve-m-e-and-bio-co-host-long-covid-what-will-it-take-to-accelerate-therapeutic-progress/
CATEGORIES:Long Covid,Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/01/Sample-Bio-Graphic.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220519
DTEND;VALUE=DATE:20220520
DTSTAMP:20260715T122619
CREATED:20220302T010059Z
LAST-MODIFIED:20220517T205140Z
UID:33477-1652918400-1653004799@solvecfs.org
SUMMARY:Signature Event: Long Covid: Research\, Policy and Economic Impact
DESCRIPTION:The Global Interdependence Center\, in partnership with the Solve Long Covid Initiative\, is continuing our conference series exploring the pandemic’s long-term healthcare\, policy\, and economic impact\, specifically the implications of long haul COVID or long COVID. Together\, we invite you to join us for the signature event of this series\, an in-person conference in New York City on Thursday\, May 19\, 2022. \nThe purpose of our conference is to raise awareness of Long Covid by examining the science and research behind it and we hope can join us through one of our registration options\, including in-person or virtual attendance. For those joining us in person\, we are delighted to provide a Patient Rest Area on site at the event. This quiet space will be a rest area for patients who need to step away for flare-up/sensory overload equipped with cots/chairs/blankets. \nSession topics of the conference will include: \n\nA special report from the Solve Long Covid Initiative\nDefining/diagnosing Long Covid\nThe economic recovery and the policy response\nScientific research\nOutlook for the labor force and labor market challenges\nThe human experience\nIndustry specific implications for:\n\nHealth insurers and health care\nPharmaceuticals\nPolicymakers and government officials\n\n\n\nLearn more and register here. \nSpecial thanks to our sponsor\, Responsum Health\, a customized\, uniquely individualized chronic disease patient platform\, for providing streaming services for this event. 
URL:https://solvecfs.org/event/signature-event-long-covid-research-policy-and-economic-impact/
CATEGORIES:Advocacy Month 2022,Conference,Long Covid,Solve M.E. Leadership
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/03/GIC-sig-event.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Shanghai:20220421T100000
DTEND;TZID=Asia/Shanghai:20220421T110000
DTSTAMP:20260715T122619
CREATED:20220414T161402Z
LAST-MODIFIED:20220414T221551Z
UID:34561-1650535200-1650538800@solvecfs.org
SUMMARY:CDMRP for ME/CFS: Navigating the Grant Application Process
DESCRIPTION:The FY22 Defense Appropriation provides funding to support therapeutic research related to medical threats\, and treatments for Service Members in current and future battlefield settings. The managing agent for the funding opportunities is the Department of Defense Office of Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC). One of the Focus Areas for funding in FY22 is myalgic encephalomyelitis/chronic fatigue syndrome. Last year\, ME/CFS researchers received $2.5 million in funding from the Peer-Reviewed Medical Research Program. \nThis informational webinar is designed to better inform and prepare the ME/CFS research community about the Peer Reviewed Medical Research Program (PRMRP) and the grant application process.  Panelists include Cecilia Dupecher\, PhD (Program Manager for PRMRP at the Congressionally Directed Medical Research Programs – CDMRP) and Solve M.E.’s Oved Amitay\, Emily Taylor\, and Leslie Phillips. \nIf you have questions for our panelists\, please send them to SolveCFS@solvecfs.org.
URL:https://solvecfs.org/event/cdmrp-for-me-cfs-navigating-the-grant-application-process/
CATEGORIES:Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/jpeg:https://solvecfs.org/wp-content/uploads/2022/04/CDMRPTwitter.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20211215T090000
DTEND;TZID=America/Los_Angeles:20211215T100000
DTSTAMP:20260715T122619
CREATED:20211213T141506Z
LAST-MODIFIED:20220107T001511Z
UID:22899-1639558800-1639562400@solvecfs.org
SUMMARY:Emily Taylor Interview with WYPR's Midday
DESCRIPTION:Solve M.E. Vice President of Advocacy and Community Engagement Emily Taylor joins WYPR’s Midday host Tom Hall on Wednesday\, December 15\, from 12-1 pm ET / 9-10 am PT for a live radio conversation about our efforts to assist survivors with Long Covid and other post-infection chronic diseases. Also joining the conversation will be Long Covid Alliance member Chimére L. Smith.  \nListen to the interview here.
URL:https://solvecfs.org/event/emily-taylor-live-interview-with-wyprs-midday/
CATEGORIES:Long Covid,Media,Solve M.E. Leadership
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2018/03/emily-e1637691757648.png
END:VEVENT
END:VCALENDAR